SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Abildgaard Niels) ;pers:(Remes Kari)"

Sökning: WFRF:(Abildgaard Niels) > Remes Kari

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Gregersen, Henrik, et al. (författare)
  • Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
  • 2022
  • Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 108:1, s. 34-44
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 -> 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5-NR) in the carfilzomib-dexamethasone maintenance group and 16.7 months (14.4-21.8) in the control group (HR 0.46, 95% CI 0.30-0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.
  •  
3.
  • Mellqvist, Ulf-Henrik, et al. (författare)
  • Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 121:23, s. 4647-4654
  • Tidskriftsartikel (refereegranskat)abstract
    • The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the andgt;= VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911.
  •  
4.
  •  
5.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5
Typ av publikation
tidskriftsartikel (3)
konferensbidrag (2)
Typ av innehåll
refereegranskat (4)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Abildgaard, Niels (5)
Waage, Anders (5)
Nahi, Hareth (5)
Gregersen, Henrik (5)
Remes, Kari (5)Ta bort avgränsningen
Guldbrandsen, Nina (4)
visa fler...
Lenhoff, Stig (3)
Turesson, Ingemar (3)
Carlson, Kristina (3)
Mellqvist, Ulf-Henri ... (3)
Westin, Jan (3)
Ahlberg, Lucia (3)
Forsberg, Karin (3)
Laane, Edward (3)
Gruber, Astrid (3)
Gedde-Dahl, Tobias (3)
Andersen, Niels Fros ... (3)
Hjertner, Oyvind (3)
Steingrimsdottir, Hl ... (3)
Haukas, Einar (3)
Hansson, Markus (2)
Axelsson, Per (2)
Linder, Olle (2)
Carlsson, Kristina (2)
Gimsing, Peter (2)
Blimark, Cecilie (2)
Eshoj, Henrik Rode (2)
Schjesvold, Fredrik (2)
Vangsted, Annette Ju ... (2)
Helleberg, Carsten (2)
Stromberg, Olga (2)
Peceliunas, Valdas (2)
Nesthus, Ingerid (2)
Frost Andersen, Niel ... (2)
Silvennoinen, Raija (2)
Toffner-Clausen, Nil ... (2)
Klausen, Tobias Wire ... (1)
Gulbrandsen, Nina (1)
Dahl, Inger-Marie (1)
Nielsen, Lene Kongsg ... (1)
Frølund, Ulf Christi ... (1)
Frolund, Ulf Christi ... (1)
Blimark, Cecilie Hve ... (1)
Crafoord, Jacob (1)
Tsykunova, Galina (1)
Lindas, Roald (1)
Kvam, Ann Kristin (1)
Dahl, Inge Marie (1)
visa färre...
Lärosäte
Karolinska Institutet (4)
Uppsala universitet (3)
Linköpings universitet (2)
Lunds universitet (2)
Umeå universitet (1)
Språk
Engelska (5)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy